__NUXT_JSONP__("/drugs/Mirvetuximab_Soravtansine", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1453084-37-1",chebiId:b,chemicalFormula:b,definition:"An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly\u002Fdisassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.",fdaUniiCode:"98DE7VN88D",identifier:"C102566",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129823","C1512"],synonyms:["IMGN853","M9346A-sulfo-SPDB-DM4","MIRVETUXIMAB SORAVTANSINE",c]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FMirvetuximab_Soravtansine",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Mirvetuximab_Soravtansine","","Mirvetuximab Soravtansine","2021-10-30T13:17:09.563Z")));